James McArthur
Chief Executive Officer at PEPGEN INC.
Net worth: 19 820 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Mott | M | 58 |
Cydan LLC
 Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | 5 years |
| Mette Agger | F | 59 |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | 6 years |
| Barbara Dalton | M | 69 |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | - |
| Sara Nayeem | M | 75 |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | 6 years |
| Matthew John Andrew Wood | M | 61 |
Pepgen Ltd.
 Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | 6 years |
| Habib Dable | M | 54 | 2 years | |
| Mary Beth DeLena | F | - | - | |
| Heidi Henson | F | 58 | 3 years | |
| Joshua Resnick | M | 49 | - | |
| Christopher Ashton | M | 64 | 5 years | |
| Laurie Keating | F | 70 | 2 years | |
| Caroline Godfrey | M | 44 |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | - |
| Jeffrey Foy | M | - | - | |
| Michelle Mellion | M | - | 2 years | |
| Niels Svenstrup | M | 54 | 3 years | |
| Jane Larkindale | M | - | - | |
| Isami Salcedo | F | - | - | |
| Noel Donnelly | M | 54 | 3 years | |
| Paul E. Avery | M | 64 |
The Friedreich's Ataxia Research Alliance
 The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | - |
| Ramin Farzaneh-Far | M | 47 |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | - |
| Thomas Hamilton | M | 56 |
The Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | - |
| Howard Mayer | M | 62 | 1 years | |
| Doug Onsi | M | 55 |
Adheron Therapeutics, Inc.
 Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | 16 years |
| Jennifer Good | F | 59 |
The Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | 13 years |
| Derek Hennecke | M | - |
The Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | - |
| Jenny Marlowe | M | 47 |
The Friedreich's Ataxia Research Alliance
The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Rahul Ballal | M | 46 | - | |
| Michael Gray | M | 53 | - | |
| Cristina Csimma | M | 65 |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | - |
| Joseph J. Vallner | M | 76 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Chris Hollowood | M | 50 | 6 years | |
| Mitchell Finer | M | 65 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 10 years |
| David Lubner | M | 60 | 2 years | |
| David Bonita | M | 48 | - | |
| Edward Conner | M | 51 | 3 years | |
| Senthil Sundaram | M | 46 | 2 years | |
| Mark Chin | M | 42 | 4 years | |
| Carl Goldfischer | M | 65 | - | |
| Scott Whitcup | M | 64 | 2 years | |
| R. Greer | M | 65 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 5 years |
| Paula Cobb | F | 51 | 1 years | |
| Bryan Yoon | M | 46 | 2 years | |
| Tu Yen Ong | M | 49 | 2 years | |
| Willem H. Scheele | M | 63 | 1 years | |
| Mark de Rosch | M | 61 | 1 years | |
| Gregory Robinson | M | 65 | 3 years | |
| Karin Jooss | M | 59 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 8 years |
| Trevor Anthony Mill | M | 53 | 1 years | |
| Lynn E. Bayless | F | - | 2 years | |
| Steven John Green | M | 47 | 1 years | |
| Frank Waligora | M | - | - | |
| Margo Roberts | M | 69 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 8 years |
| Rabia Ozden | M | 56 | - | |
| David Warren Carter | M | 84 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 years |
| Kevin Johnson | M | 60 | 2 years | |
| Thomas Shenk | M | 77 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 8 years |
| Peter K. Working | M | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Kristen Hege | M | 60 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 years |
| James M. Gower | M | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 13 years |
| John T. Potts | M | 92 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 years |
| Inder Mohan Verma | M | 76 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 years |
| Dale G. Ando | M | 70 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Daniel F. Hoth | M | 78 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 years |
| Gautam Banik | M | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 11 years |
| Nancy M. Crowell | F | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 9 years |
| Robert H. Tidwell | M | 80 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 9 years |
| Aya Jakobovits | M | 71 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 10 years |
| Lesley A. Stolz | M | 60 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 1 years |
| Michael W. Ramsay | M | 67 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 6 years |
| Linda R. Judge | F | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| Shirley M. Clift | F | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 years |
| Shawn Stetson | M | 47 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 55 | 76.39% |
| United Kingdom | 18 | 25.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James McArthur
- Personal Network
